Clinical trials: Geriatric Cancer Patients
Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
The purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans.
- Trial name
- NCT02494882
- Testing
- Ruxolitinib, Dasatinib, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
The investigators compare the overall survival between combination chemotherapy and monochemotherapy as a first-line chemotherapy in elderly patients with metastatic or recurrent gastric cancer.
- Trial name
- NCT02114359
- Testing
- Capecitabine/cisplatin, S-1/cisplatin, Capecitabine/oxaliplatin
- Where
- 14 sites in South Korea
- Volunteers
- 111 people
- Sponsor
- Seoul National University Hospital
Diffuse Large B-Cell Lymphoma
Mini-CHOP and Rituximab in Patients Aged Over 80 Years
The purpose of the study is to evaluate efficacy and safety of R-miniCHOP for elderly patients with diffuse large B-Cell lymphoma (DLBC) Lymphoma aged over 80 years by measuring the overall survival.
- Trial name
- NCT01087424
- Testing
- R mini CHOP
- Volunteers
- 150 people
- Sponsor
- Lymphoma Study Association
Bladder Cancer, Metastatic Bladder Cancer
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
- Trial name
- NCT06138561
- Testing
- Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This phase II, open-label, multicenter study evaluates zanubrutinib in patients aged 80 years and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who require treatment.
- Trial name
- ZEN-CLL (NCT07739459)
- Testing
- Zanubrutinib
- Where
- 17 sites in France
- Volunteers
- 95 people
- Sponsor
- The Lymphoma Academic Research Organisation
B-Cell Chronic Lymphocytic Leukemia
Rituximab in Pretreated Elderly or Unfit B-CLL Patients
The study will test the efficacy rituximab in addition to glucocorticoids for the treatment of B-CLL in elderly or unfit patients.
- Trial name
- NCT01576588
- Testing
- Rituximab, Glucocorticoid
- Where
- Lithuania
- Volunteers
- 25 people
- Sponsor
- Prof. Dr. Med. Laimonas Griskevicius
Primary Brain Tumor, Glioblastoma
Temozolomide in Elderly Patients With KPS < 70
The management of glioblastoma in elderly patients with poor performance status (KPS<70) is unsettled. This single arm phase 2 trial trial was designed to evaluate the efficacy and safety of temozolomide alone in this population
- Trial name
- TAG (NCT01242566)
- Testing
- Temozolomide
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Chronic Lymphocytic Leukemia
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT01013961
- Testing
- alemtuzumab, rituximab
- Where
- 102 sites in United States
- Volunteers
- 31 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer
Telemonitoring of Geriatric Cancer Patients Using Handheld Devices
Cancer is becoming a chronic disease, with the requirement of a lifelong intake of cancer-controlling drugs. While young(er) patients may cope with this, geriatric cancer patients may require a more customized and tailored follow…
- Trial name
- NCT03196050
- Testing
- Handheld Device (Smart Phone)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsmedizin Mannheim
Cancer
A Single Arm Pilot Trial of a Social Network Intervention
The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust \& Adherence or SONATA) is helpful for older individuals receiving cancer treatment.
- Trial name
- SONATA (NCT05745038)
- Testing
- SONATA
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of Rochester
Cancer
Antineoplastic Drugs in Elderly Patients
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend…
- Trial name
- NCT05467189
- Testing
- Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shandong University
Chronic Lymphatic Leukemia
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation
To study the safety and efficacy of anti-CD20 blockade with ofatumumab in the context of allogeneic HCT in CLL
- Trial name
- NCT01809847
- Testing
- Ofatumumab
- Where
- 11 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Technische Universität Dresden
Leukemia, Myeloid, Acute
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
Acute myeloid leukemia (AML) is a group of heterogeneous malignancies derived from hematopoietic precursors. Patients older than 65 years can hardly benefit from standard intensive chemotherapy while having a poor toxicity…
- Trial name
- NCT04824924
- Testing
- The combination of HHT, venetoclax, AZA, G-CSF
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Leukemia
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00017589
- Testing
- oblimersen sodium, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Genta Incorporated
75 Years Old and More, Cancer
Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)
Many cancers are diagnosed after 75 years. Treatment in chemotherapy begins without evidence of geriatric risk factors. A new tool for screening for geriatric fragilities is used, a self-administered questionnaire carried out by…
- Conditions
- 75 Years Old and More, Cancer, Chemotherapy
- Trial name
- D-FOG (NCT03261128)
- Testing
- Self-questionnaire
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Poitiers University Hospital
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Tumor, Health Services Research
Care Pathways and Disparities in Care for Older Patients With Cancer: Typology, Determinants and Effect on Prognosis ( PASSAGE )
More than half of new cases of cancer in Europe in 2022 occurred in people aged over 70. In addition to cancer, the majority of older people have one or more illnesses that may interact with the treatment decision, cancer…
- Conditions
- Tumor, Health Services Research, Causality, Geriatric Assessment
- Trial name
- PASSAGE (NCT07092800)
- Where
- France
- Volunteers
- 75,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B Cell Lymphoma
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and…
- Trial name
- NCT06530511
- Testing
- Polatuzumab vedotin, Rituximab, Orelabrutinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
5-azacytidine treatment prolongs survival in patients with myelodysplastic syndrome (MDS), but does not cure the disease. Allogeneic stem cell transplantation is a curative treatment option but is associated with a high risk…
- Trial name
- NCT01404741
- Testing
- allogeneic stem cell transplantation, 5-azacytidine until progress
- Where
- 17 sites in Germany
- Volunteers
- 191 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.